Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3084% below fair value
$3.01−0.23 (-7.10%)
Close on Nov 13, 2026Market cap $51.62MP/E –Yield –
Tonix Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Tonix Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2026 was -420.4%. For fiscal 2025 it was -946.2%, against -1288.3% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -946.2% | +342.0 |
| FY2024 | Dec 31, 2024 | -1288.3% | +213.5 |
| FY2023 | Dec 31, 2023 | -1501.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -309.4% | +663.5 |
| Q2 FY2026 | Jun 30, 2026 | -299.4% | +1115.6 |
| Q1 FY2026 | Mar 31, 2026 | -584.4% | +108.5 |
| Q4 FY2025 | Dec 31, 2025 | -870.3% | −14.1 |
| Q3 FY2025 | Sep 30, 2025 | -972.9% | −469.3 |
| Q2 FY2025 | Jun 30, 2025 | -1415.0% | +2152.7 |
| Q1 FY2025 | Mar 31, 2025 | -692.8% | −90.9 |
| Q4 FY2024 | Dec 31, 2024 | -856.2% | −133.2 |
| Q3 FY2024 | Sep 30, 2024 | -503.6% | +197.7 |
| Q2 FY2024 | Jun 30, 2024 | -3567.8% | – |
| Q1 FY2024 | Mar 31, 2024 | -601.9% | – |
| Q4 FY2023 | Dec 31, 2023 | -723.0% | – |
| Q3 FY2023 | Sep 30, 2023 | -701.3% | – |
See a number that looks wrong?